Combigene AB (COMBI) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.087x

Based on the latest financial reports, Combigene AB (COMBI) has a cash flow conversion efficiency ratio of -0.087x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.23 Million ≈ $-670.56K USD) by net assets (Skr71.58 Million ≈ $7.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Combigene AB to measure how many days the company can operate on defensive assets alone.

Combigene AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Combigene AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Combigene AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Combigene AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CF Energy Corp V:CFY	0.026x
VIA OPTRONICS AG SP.ADS/1 F:5UU1	N/A
Dangee Dums Limited NSE:DANGEE	0.140x
ARK Resources Bhd KLSE:7007	0.256x
TV Thunder Public Company Limited BK:TVT	0.002x
Merino & Co. Ltd AU:MNC	-0.297x
Can Fite Biopharma Ltd TA:CANF	-0.425x
Hub Cyber Security Ltd. Ordinary Shares NASDAQ:HUBC	0.109x

Annual Cash Flow Conversion Efficiency for Combigene AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Combigene AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see COMBI stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Combigene AB

ST:COMBI Sweden Biotechnology

Market Cap

$5.24 Million

Skr48.71 Million SEK

Market Cap Rank

#28475 Global

#645 in Sweden

Share Price

Skr2.46

Change (1 day)

+1.23%

52-Week Range

Skr2.31 - Skr2.49

All Time High

Skr152.75